Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 07:47pm CEST

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

 
   By Joseph Walker and Melodie Warner 
 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
04/21CELGENE SHAREHOLDER ALERT BY FORMER : Kahn Swick & Foti, LLC Reminds Investors ..
BU
04/20Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commenc..
BU
04/20CELGENE CORPORATION : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Rem..
AC
04/20CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences
AQ
04/19BRAGAR EAGEL & SQUIRE, P.C. : Reminds Investors That a Class Action Lawsuit Has ..
BU
04/19CELGENE CORP /DE/ : Change in Directors or Principal Officers (form 8-K)
AQ
04/19CELGENE CORPORATION : Announces Changes to Its Board of Directors
BU
04/17CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences
BU
04/13BEIGENE : Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in P..
AQ
04/13CELGENE : MorphoSys Nominates New Candidates for Supervisory Board
AQ
More news
News from SeekingAlpha
01:00pCELGENE : Bold Pursuits In Science With 24.66% Discount 
04:26aCELGENE : Will Tremfya Punish Otezla Too? 
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/17Evelo Biosciences Files For U.S. IPO 
04/17PROJECT $1M : Q1 2018 Has Been A Rollercoaster Ride! 
Financials ($)
Sales 2018 14 806 M
EBIT 2018 8 489 M
Net income 2018 5 310 M
Debt 2018 369 M
Yield 2018 -
P/E ratio 2018 13,01
P/E ratio 2019 10,82
EV / Sales 2018 4,54x
EV / Sales 2019 3,64x
Capitalization 66 906 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 116 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Gilla Kaplan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-14.77%66 906
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571